Fig. 3: Peptide editing and allosterically coupled MHC I glycan processing by GluII in the PLC.
From: Molecular basis of MHC I quality control in the peptide loading complex
a Peptide binding and proofreading of HLA-A*03:01 associated with the PLC reconstituted in lipid nanodiscs (75 nM of PLC) monitored by fluorescence polarization using equimolar concentrations of fluorescent reporter peptides: high-affinity epitope CFSN (AIFCFSNMTK) or low-affinity HLA-B*27:01-restricted epitope C4F (RRYCFKSTEL). For peptide editing, a 2000-fold molar excess of unlabeled high-affinity peptide (150 µM CSN, AIFCSNMTK) or low-affinity peptide (150 µM R9L, RRYQKSTEL, black trace) were used. b LC-MS analysis of HLA-A*03:01 glycan status during glycan processing. c The percentage of the Glc1Man9GlcNAc2-modified HLA-A*03:01 is given as mean (n = 2). The data are representative of two biological replicas. Source data are provided as a Source Data file (a) or in the Zenodo open access repository (b, c).
